Savara Inc. $SVRA Position Increased by Farther Finance Advisors LLC

Farther Finance Advisors LLC lifted its holdings in Savara Inc. (NASDAQ:SVRA) by 17.6% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 38,001 shares of the company’s stock after buying an additional 5,687 shares during the quarter. Farther Finance Advisors LLC’s holdings in Savara were worth $87,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of SVRA. Ameriprise Financial Inc. acquired a new stake in Savara during the fourth quarter worth about $37,000. Brooklyn Investment Group acquired a new stake in shares of Savara during the 1st quarter worth approximately $65,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Savara during the 1st quarter worth approximately $74,000. Stonepine Capital Management LLC bought a new stake in shares of Savara in the 1st quarter worth approximately $81,000. Finally, Jump Financial LLC boosted its position in Savara by 214.1% during the 1st quarter. Jump Financial LLC now owns 65,200 shares of the company’s stock valued at $181,000 after purchasing an additional 44,445 shares during the period. Institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. HC Wainwright increased their target price on Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Oppenheimer increased their price objective on shares of Savara from $6.00 to $8.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Saturday, September 27th. Finally, Guggenheim upped their target price on shares of Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and an average target price of $7.50.

Savara Stock Performance

NASDAQ SVRA opened at $3.49 on Friday. Savara Inc. has a twelve month low of $1.89 and a twelve month high of $4.30. The company has a debt-to-equity ratio of 0.25, a quick ratio of 11.08 and a current ratio of 11.08. The stock has a market cap of $603.21 million, a price-to-earnings ratio of -6.98 and a beta of 0.46. The firm’s 50 day moving average price is $3.22 and its two-hundred day moving average price is $2.84.

Savara (NASDAQ:SVRA) last released its earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Equities analysts anticipate that Savara Inc. will post -0.45 EPS for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.